within 16 days of discharge, prolonged catheter use, catheter reinsertion rates, and price-standardized 90 day episode costs for those who did and did not receive home care. Routine home care was defined as home care initiated within 4 days of discharge among patient discharged without a drain. RESULTS: We identified 647 patients meeting our inclusion criteria, of whom 13% received home health care. Patient and cancer characteristics were similar between cohorts (Table 1) . Use of routine home care after prostatectomy varied from 0 to 53% across 33 practices in MUSIC (p¼0.05). Unadjusted, patients with home care had increased rates of ED visits within 16 days (15.5% vs 6.9%, p<0.01), similar rates of catheter duration > 16 days (3.6% vs 3.0%, p¼0.79) and need for catheter replacement (1.2% vs 2.5%, p¼0.46), and a trend toward decreased readmissions rates (0 vs 4.1%, p¼0.06). After controlling for patient and cancer characteristics, only the increased rate of ED visits remained significant (p<0.01). . Home health care cost an average of $1,000 per episode. Average total episode cost were $15,556 with home care and $13,788 without it. There were no differences in index hospitalization costs.
INTRODUCTION AND OBJECTIVES: Millions of patients take prescription medications each year for common urologic conditions. Generic and brand name drugs often have widely divergent pricing despite similar therapeutic benefit and side effect profiles. Because prescriptions will only increase as the US population ages, we examined urologist prescription patterns for generic and brand name drugs used to treat three common urologic conditions, and consequent economic implications for Medicare Part D spending.
METHODS: We extracted all 2014 urologist prescription claims and payments from the Medicare Part D Prescriber Public Use File. We categorized oral medications used to treat three urological conditions: benign prostate enlargement, erectile dysfunction, and overactive bladder. We then examined total claims, payments, and 30 day cost for each medication with at least 1,000 prescription claims. Last, we estimated the excess annual Medicare Part D payments associated with use of non generic and higher cost medications. We selected a low cost and/or generic drug as a cost comparator for each drug class, then calculated the difference between the actual cost of non comparator drugs and the cost of equivalent length prescriptions of the comparator.
RESULTS: The total claims, total payments, and 30 day cost for medications by urologic condition are shown (Table) . Within drugs for benign prostate enlargement, the excess Medicare Part D payment for drugs other than generic tamsulosin or finasteride was $158,935,926. Among erectile dysfunction medications, the excess payment for drugs other than Levitra was $3,105,023. Within drugs for overactive bladder, the excess payment for drugs other than generic oxybutynin extendedrelease was $248,430,484. The total excess Medicare Part D prescription payment for higher cost and non generic drugs prescribed by urologists in 2014 was $410,471,433.
CONCLUSIONS: Among Medicare Part D beneficiaries, we found excess payments for higher cost and non generic drugs prescribed by urologists for three common conditions approached a half billion US dollars. Increasing low cost and generic drug use where available evidence is equivocal represents a promising policy target to reduce Part D medication spending.
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